Lupin launches Lurasidone Hydrochloride tablets in US

21 Feb 2023 , 02:47 AM

Lupin Limited today announced the launch of Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, as a generic equivalent to Sunovion Pharmaceuticals, Inc.’s Latuda Tablets. 

In the United States, Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg (RLD Latuda) had an estimated annual sales of USD 4.2 billion, as per IQVIA MAT December 2022.

Lupin develops and commercializes a varied range of branded and generic formulations, biotechnology products, and APIs in over 100 markets worldwide, including India, the United States, South Africa, Latin America (LATAM), Asia Pacific (APAC), Europe, and the Middle East.

In FY22, the company spent 8.7% of its revenue on research and development.

At around 2.44 PM, Lupin was trading at Rs668.80, up by 0.25% against the previous close of Rs667.10 on NSE. The counter touched an intraday high and low of Rs674.05 and Rs662.25 respectively.

For feedback and suggestions, write to us at [e-mail]